Camptothecin

SKU: orb1309690

Description

Camptothecin

Research Area

Cell Biology, Epigenetics & Chromatin, Infectious Disease & Virology, Molecular Biology

Key Properties

• CAS Number: 7689-03-4
• MW: 348.35
• Purity: 98.61%
• Formula: C₂₀H₁₆N₂O₄
• SMILES: C(C)[C@]1(O)C2=C(C(=O)N3C(=C2)C=4C(C3)=CC=5C(N4)=CC=CC5)COC1=O
• Target: Influenza Virus,Topoisomerase,Antifungal,Antibiotic,Apoptosis,MicroRNA,ADC Cytotoxin
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:0.5 mg/mL (1.44 mM);DMSO:5 mg/mL (14.35 mM)

Bioactivity

• Target IC50:
  HCC1419 cells:0.067 µM|HCC1428 cells:0.448 µM|HCC202 cells:0.481 µM|MDA453 cells:0.058 µM|Topo I:0.68 μM|BT-549 cells:0.056 µM|MCF-7 cells:0.089 µM|MDA231 cells:0.04 µM|Sum149 cells:0.065 µM
• In Vivo:
  METHODS: To assay antitumor activity in vivo Camptothecin (0.15-1.2 mg/kg) and doxorubicin (0.25-2 mg/kg) were intravenously injected into athymic n-/- mice bearing triple-negative mammary carcinoma tumors, MDA-MB-231, every two days for four administrations. Results: A dose-dependent reduction in tumor growth was observed, with a 40.8% reduction at 0.5 mg/kg DOX + 0.3 mg/kg CPT and a 93% reduction at 1.5 mg/kg DOX + 0.9 mg/kg CPT the highest dose tested (2 mg/kg DOX + 1.2 mg/kg CPT) completely stopped tumor growth on day 44. METHODS: To stud the effects on obesity, Camptothecin (1 mg/kg, 0.1% Tween 80) was administered orally to obese mice once daily for three days. Results: Oral administration of Camptothecin increased circulating GDF15 levels in diet-induced obese (DIO) mice and genetic ob/ob mice. Consistent wit the anorectic effects of GDF15, Camptothecin inhibited food intake, thereby reducing body weight, blood glucose, and liver fat content in obese mice.
• In Vitro:
  METHODS: Eight TNBC cell lines were treated with Camptothecin (0.1-5 µM) for 72 h. Cell viability was measured by PrestoBlue. Results: Camptothecin inhibite the cell viability of MCF7, HCC1428, HCC1419, HCC202, MDA453, MDA231, Sum149, and BT549 cells, with IC50 Values of 0.089/0.448/0.067/0.481/0.058/0.040/0.065/ 0.056 µM. METHODS: Lung cancer cells H1299 and H460 were treated with Camptothecin (0.5-5 µM) for 16 h. Cell migration was detected by wound-healing assay. Results: Camptothecin inhibite the migration of H1299 and H460 cells without a dose-dependent effect.
• Cell Research:
  Tumor cells are plated in 100 μL of medium in 96-well microtiter plates at a density of 1500 to 4000 cells per well and allowed to adhere overnight. Cells are incubated with Camptothecin for 48 hours and then with fresh medium for 48 hours. Camptothecin at Each concentration is added in quadruplicate. Following a 4-hour incubation of treated cells with MTT the reduced dye product is extracted fro the cells with 0.2 ml of DMSO followed by 50 μL of Sorensen's buffer the plates are shaken Briefly, an the absorbance at 570 nM is read and quantitated. Curves are fitted to the MTT assay data using a four-parameter logistic equation.(Only for Reference)

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Disclaimer: For research use only

Alternative Names

CPT, DNA topoisomerase I, (S)-(+)-Camptothecin, ADC Cytotoxin, alkaloid, ADCCytotoxin, Apoptosis, Antibiotic, Camptothecin, Campathecin, Fungal, HIF-1α, NSC100880, NSC-100880, NSC 100880, InfluenzaVirus, Influenza Virus, microRNAs, MicroRNA, miRN, miRNA, Topoisomerase, Topo I, Top1

Compound Identifiers

PubChem CID

24360